Healthcare investment powerhouse Deerfield Management has forged a strategic partnership with Amazon Web Services (AWS) to provide AI and cloud infrastructure across its portfolio of more than 200 healthcare and life sciences companies. The collaboration positions AWS as the preferred AI provider for Deerfield's investment ecosystem, potentially accelerating the deployment of artificial intelligence tools across drug development, clinical operations, and patient care delivery.

The partnership grants Deerfield portfolio companies access to AWS's suite of generative AI services, technical training programs, and specialized healthcare tools including Amazon Bio Discovery and Amazon Bedrock AgentCore for building AI agents. According to the announcement, the focus centers on "agentic AI" applications—autonomous systems designed to execute complex healthcare workflows with minimal human intervention.

Building an AI-Enabled Investment Ecosystem

Deerfield's internal teams, including Deerfield Intelligence and Deerfield Discovery and Development (3DC), will receive direct access to AWS AI and cloud technology as part of the arrangement. The partnership comes as Deerfield continues expanding its healthcare technology footprint. In May 2025, the firm unveiled its third healthcare innovations fund with over $600 million earmarked for therapeutics and technologies.

"This collaboration will empower our portfolio companies to harness the full potential of AI and cloud technologies, driving innovation and improving outcomes across the healthcare landscape," said Jim Flynn, Managing Partner at Deerfield Management, according to the announcement.

Mark Michalski, M.D., who serves as Chief Information Officer at Deerfield, emphasized the strategic importance of the partnership for accelerating AI adoption across the firm's diverse healthcare investments.

From Administrative Automation to Drug Discovery

At least one Deerfield-backed company is already leveraging AWS infrastructure for clinical applications. Ascertain, a portfolio company led by Michalski as CEO, uses AWS to power its agentic AI platform that automates case management and prior authorization workflows—administrative tasks that have long burdened healthcare providers.

The partnership's scope extends beyond administrative efficiency to encompass drug discovery applications through tools like Amazon Bio Discovery, suggesting Deerfield aims to create standardized AI infrastructure across both clinical and research operations within its portfolio companies.

Dan Sheeran, Vice President and General Manager of Healthcare and Life Sciences at AWS, noted that the collaboration would provide Deerfield's portfolio companies with "the most advanced AI and cloud capabilities" to transform healthcare delivery and accelerate innovation.

Implications for Healthcare AI Deployment

The arrangement reflects a broader trend of investment firms building shared technology infrastructure to accelerate portfolio company growth. For healthcare startups within Deerfield's ecosystem, the partnership potentially lowers barriers to accessing enterprise-grade cloud computing and AI capabilities that might otherwise require significant capital investment.

Deerfield operates from Cure, a healthcare innovation campus in New York City that serves as a hub for the firm's portfolio companies and internal teams. The AWS partnership adds a digital infrastructure layer to this physical innovation ecosystem, creating what amounts to a standardized AI development environment across hundreds of healthcare organizations.

As healthcare organizations increasingly explore autonomous AI systems for clinical and operational workflows, the partnership signals investor confidence in cloud-based AI infrastructure as foundational to the next generation of healthcare technology companies.

Sources

  1. Deerfield taps AWS to fuel healthcare AI ambitions — Fierce Healthcare